NASDAQ:KALA Kala Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.33 +0.02 (+6.49%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$0.31▼$0.3450-Day Range$0.30▼$0.7852-Week Range$0.28▼$4.84Volume1.32 million shsAverage Volume1.85 million shsMarket Capitalization$23.81 millionP/E RatioN/ADividend YieldN/APrice Target$3.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Kala Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside852.7% Upside$3.13 Price TargetShort InterestHealthy5.92% of Float Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1.42 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.99 out of 5 starsMedical Sector486th out of 1,433 stocksPharmaceutical Preparations Industry232nd out of 683 stocks 3.2 Analyst's Opinion Consensus RatingKala Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.13, Kala Pharmaceuticals has a forecasted upside of 852.7% from its current price of $0.33.Amount of Analyst CoverageKala Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.92% of the float of Kala Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKala Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kala Pharmaceuticals has recently decreased by 29.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKala Pharmaceuticals does not currently pay a dividend.Dividend GrowthKala Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKala Pharmaceuticals has received a 66.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Glucocorticoids" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kala Pharmaceuticals is -1.35. Previous Next 1.1 News and Social Media Coverage News SentimentKala Pharmaceuticals has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kala Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 12 people have searched for KALA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Kala Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kala Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,418,911.00 in company stock.Percentage Held by Insiders30.55% of the stock of Kala Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.81% of the stock of Kala Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kala Pharmaceuticals are expected to grow in the coming year, from ($1.33) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kala Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kala Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKala Pharmaceuticals has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Kala Pharmaceuticals (NASDAQ:KALA) StockKala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.Read More KALA Stock News HeadlinesJuly 6, 2022 | finance.yahoo.comKala Pharma (KALA) Moves to Buy: Rationale Behind the UpgradeJune 2, 2022 | finance.yahoo.comKala Pharmaceuticals to Present at Jefferies Healthcare ConferenceMay 27, 2022 | nasdaq.comBitcoin Now Buys You the Greatest Amount of Kala Pharmaceuticals in the Past YearMay 24, 2022 | seekingalpha.comH.C. Wainwright analyst lowers Kala Pharmaceuticals' price targetMay 23, 2022 | uk.investing.comWhy Kala Pharmaceuticals Shares Are Rising TodayMay 23, 2022 | finance.yahoo.comThis Biopharma Stock Surges After Offloading Its Ophthalmic Eye Drop PortfolioMay 23, 2022 | nasdaq.comAlcon To Acquire EYSUVIS, INVELTYS From Kala PharmaMay 23, 2022 | seekingalpha.comKala Pharmaceuticals plans to sell EYSUVIS and INVELTYS to AlconMay 17, 2022 | seekingalpha.comKala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call TranscriptMay 17, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Kala PharmaceuticalsMay 16, 2022 | seekingalpha.comKala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | benzinga.comRecap: Kala Pharmaceuticals Q1 EarningsMay 15, 2022 | markets.businessinsider.comWhat Wall Street expects from Kala Pharmaceuticals's earningsMay 13, 2022 | seekingalpha.comKala Pharmaceuticals Q1 2022 Earnings PreviewMay 9, 2022 | finance.yahoo.comKala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference CallMay 3, 2022 | seekingalpha.comKala expands commercial, Medicare coverage for dry eye disease therapy EysuvisMay 3, 2022 | finance.yahoo.comKala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®May 2, 2022 | uk.investing.comFDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD PatientsMay 2, 2022 | uk.investing.comKala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular DiseasesMay 1, 2022 | finance.yahoo.comKala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual MeetingApril 27, 2022 | finance.yahoo.comKala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseApril 4, 2022 | finance.yahoo.comKala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual MeetingMarch 31, 2022 | benzinga.com5KALA : Kala Pharmaceuticals's Return On Capital Employed InsightsMarch 30, 2022 | benzinga.comJP Morgan Downgrades Kala Pharmaceuticals to Underweight, Announces $1.5 Price TargetMarch 29, 2022 | markets.businessinsider.comKala Pharmaceuticals earnings: here's what Wall Street expectsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALA CUSIPN/A CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees192Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/06/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$3.13 High Stock Price Forecast$4.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+852.7%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,600,000.00 Net Margins-1,552.90% Pretax Margin-1,552.90% Return on Equity-369.16% Return on Assets-87.92% Debt Debt-to-Equity Ratio5.04 Current Ratio3.00 Quick Ratio2.68 Sales & Book Value Annual Sales$11.24 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.26Miscellaneous Outstanding Shares72,594,000Free Float50,417,000Market Cap$23.81 million OptionableOptionable Beta1.01 Kala Pharmaceuticals Frequently Asked Questions Should I buy or sell Kala Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Kala Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares. View analyst ratings for Kala Pharmaceuticals or view top-rated stocks. What is Kala Pharmaceuticals' stock price forecast for 2022? 3 Wall Street research analysts have issued 1-year target prices for Kala Pharmaceuticals' shares. Their KALA stock forecasts range from $1.50 to $4.00. On average, they predict Kala Pharmaceuticals' share price to reach $3.13 in the next twelve months. This suggests a possible upside of 852.7% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Kala Pharmaceuticals' stock performed in 2022? Kala Pharmaceuticals' stock was trading at $1.21 at the start of the year. Since then, KALA shares have decreased by 72.9% and is now trading at $0.3280. View the best growth stocks for 2022 here. When is Kala Pharmaceuticals' next earnings date? Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Kala Pharmaceuticals. How were Kala Pharmaceuticals' earnings last quarter? Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The business earned $1.37 million during the quarter, compared to analyst estimates of $3.11 million. Kala Pharmaceuticals had a negative trailing twelve-month return on equity of 369.16% and a negative net margin of 1,552.90%. During the same period in the previous year, the firm posted ($0.49) earnings per share. View Kala Pharmaceuticals' earnings history. Who are Kala Pharmaceuticals' key executives? Kala Pharmaceuticals' management team includes the following people: Mr. Mark T. Iwicki, Chairman & CEO (Age 56, Pay $919.89k) (LinkedIn Profile)Mr. Todd Bazemore, Pres & COO (Age 52, Pay $671.58k) (LinkedIn Profile)Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer (Age 69, Pay $645.19k)Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory BoardMs. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 47) (LinkedIn Profile)Ms. Jill S. Steier, Exec. Director of Investor Relations & Corp. CommunicationsMr. Eric L. Trachtenberg, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)Ms. Michele LaRussa, Sr. VP of Regulatory Affairs & Quality Assurance (Age 52)Mr. Vincent Kosewski, Sr. VP of Manufacturing & Supply Chain Management (Age 59)Mr. James Patnoe, Sr. VP of Market Access, Commercial Operations & Pricing What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO? 1 employees have rated Kala Pharmaceuticals CEO Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among Kala Pharmaceuticals' employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Kala Pharmaceuticals' key competitors? Some companies that are related to Kala Pharmaceuticals include Cybin (CYBN), Seelos Therapeutics (SEEL), Cue Biopharma (CUE), Checkpoint Therapeutics (CKPT), NervGen Pharma (NGENF), BriaCell Therapeutics (BCTX), Anixa Biosciences (ANIX), Fortress Biotech (FBIO), GT Biopharma (GTBP), Ardelyx (ARDX), Eliem Therapeutics (ELYM), Applied Molecular Transport (AMTI), Sol-Gel Technologies (SLGL), Xilio Therapeutics (XLO) and Capricor Therapeutics (CAPR). View all of KALA's competitors. What other stocks do shareholders of Kala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV). When did Kala Pharmaceuticals IPO? (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. What is Kala Pharmaceuticals' stock symbol? Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA." How do I buy shares of Kala Pharmaceuticals? Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kala Pharmaceuticals' stock price today? One share of KALA stock can currently be purchased for approximately $0.33. How much money does Kala Pharmaceuticals make? Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $23.81 million and generates $11.24 million in revenue each year. The company earns $-142,600,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. How many employees does Kala Pharmaceuticals have? Kala Pharmaceuticals employs 192 workers across the globe. How can I contact Kala Pharmaceuticals? Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for Kala Pharmaceuticals is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399. This page (NASDAQ:KALA) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
